{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Number of participants alive at 5 years (overall survival).","groups":[{"description":"Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4.\n\nActivated marrow infiltrating lymphocytes: Administered on Days 3 and 4.\n\nCyclophosphamide: Administered at 2.5 g/m\\^2.\n\nFilgrastim: Administered post cyclophosphamide daily until leukapheresis.\n\nLeukapheresis: Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.\n\nMelphalan: 100 mg/m\\^2/day given on Days -2 and -1.\n\nAutologous stem cell transplant: Infused on Day 0.","id":"OG000","title":"ASCT + MILs"},{"description":"Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4. The allogeneic myeloma vaccine will be administered on Days 21, 60, 180, and 300.\n\nActivated marrow infiltrating lymphocytes: Administered on Days 3 and 4.\n\nAllogeneic Myeloma Vaccine: Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.\n\nCyclophosphamide: Administered at 2.5 g/m\\^2.\n\nFilgrastim: Administered post cyclophosphamide daily until leukapheresis.\n\nLeukapheresis: Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.\n\nMelphalan: 100 mg/m\\^2/day given on Days -2","id":"OG001","title":"ASCT + MILs + Vaccine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only participants who had ASCT were evaluated for response. Three participants on the ASCT + MILs arm and two participants on the ASCT + MILs + vaccine arm were removed from study prior to ASCT and were therefore not evaluable for this outcome.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}